---
title: "Hallucinations in Healthcare: Why LLMs Require Pharmacy-Specific Validation Frameworks"
author: "Learning Data"
platform: "medium"
publicationName: "Learning Data"
url: "https://medium.com/learning-data/hallucinations-in-healthcare-why-llms-require-pharmacy-specific-validation-frameworks-2aca0bdbe435?source=rss----eec44e936bf1---4"
publishedAt: "2026-02-25"
tags:
  - "ai"
  - "artificial-intelligence"
  - "healthcare"
  - "healthcare-technology"
  - "data-science"
  - "education"
---

# Hallucinations in Healthcare: Why LLMs Require Pharmacy-Specific Validation Frameworks

# **Hallucinations in Healthcare: Why LLMs Require Pharmacy-Specific Validation Frameworks**

[Rohan Desai](/@rohan-desai?source=post_page---byline--2aca0bdbe435---------------------------------------)

5 min read·18 hours ago

\--

*A look at how AI-generated errors manifest in clinical settings — and what responsible deployment requires.*

The integration of artificial intelligence into healthcare is advancing rapidly. Large language models (LLMs) are being applied across clinical workflows — from supporting drug discovery to assisting with documentation and decision support.

As with any emerging technology in a high-stakes environment, responsible deployment requires a clear-eyed understanding of both capabilities and limitations. One limitation that warrants particular attention in pharmacy settings is the phenomenon known as hallucination.

![]()

In AI systems, hallucination refers to the generation of outputs that are fluent and confident in presentation but factually incorrect. In most contexts, this represents a quality control issue.

In pharmacy, where clinical accuracy is directly tied to patient outcomes, it represents a patient safety consideration that must be addressed through deliberate design and governance.

## **What Is an AI Hallucination?**

LLMs generate responses by predicting probable word sequences based on patterns learned from large text corpora. Unlike a trained clinician, these models do not verify claims against a ground truth. They approximate — and in some cases, that approximation produces clinically incorrect responses. A stated dosage may be wrong. A drug interaction may be omitted. A contraindication may be misrepresented.

This is not a reflection of the technology’s overall capability. It is a characteristic of how current LLM architectures handle uncertainty. Without deliberate design choices to surface and communicate that uncertainty, models may generate plausible-sounding responses in areas where their training data was sparse, outdated, or ambiguous — using the same tone as when their outputs are accurate.

Understanding this characteristic is essential to deploying these tools appropriately — neither overstating the risk nor understating it.

## **Why Pharmacy Warrants Special Consideration**

Pharmacy practice involves layered, simultaneous clinical judgment: drug selection, dosing, patient-specific factors including renal and hepatic function, allergies, polypharmacy, age, diagnosis, and formulary constraints. The combination of complexity and consequence makes it a domain where AI-generated errors — even infrequent ones — carry meaningful risk.

Several categories of pharmacy-specific hallucination risk are worth understanding:

### **Dosage thresholds.**

Training data may skew toward standard adult dosing. Applying general dosing language to patients with hepatic impairment, renal dysfunction, or other modifying conditions is a known area where model outputs may diverge from clinical guidelines.

### **Drug interactions.**

Clinical knowledge in this area evolves continuously. Models trained on data from prior years may not reflect updated FDA warnings or label revisions. A gap presented as a complete answer can itself constitute a clinical error.

### **Off-label use.**

LLMs may reflect common clinical practice in the literature without clearly distinguishing between approved indications and off-label use, or between clinical trial findings and established efficacy.

### **Pediatric and geriatric populations.**

These groups are underrepresented in both clinical literature and training datasets, making extrapolated dosing guidance in these populations a higher-risk output category.

## **Validation Frameworks and Guardrails**

The risk associated with LLM hallucinations in pharmacy is real, but it is also addressable. Several technical and operational approaches are being implemented across the industry to reduce the likelihood and impact of hallucinated outputs:

### **Retrieval-Augmented Generation (RAG).**

Rather than relying solely on trained knowledge, RAG systems query verified clinical databases — such as Lexicomp, Micromedex, or institutional formularies — in real time, grounding model outputs in current, curated reference material. This reduces dependence on training data that may be incomplete or outdated.

### **Uncertainty signaling and abstention.**

A well-validated clinical AI should be capable of communicating the limits of its reliability — flagging low-confidence outputs or declining to generate a response rather than producing a plausible but unsupported answer. This behavior can be designed into a system and should be treated as a feature requirement, not an afterthought.

### **Human-in-the-loop review.**

For high-stakes clinical outputs — dosing recommendations, interaction checks, allergy assessments — maintaining pharmacist or clinician oversight in the decision loop remains appropriate. AI tools in these contexts serve most safely as decision support aids, not autonomous decision-makers.

### **Scope limitation.**

Tools scoped to specific, bounded tasks — formulary lookup, prior authorization assistance, documentation support — carry fewer failure modes than broad-purpose clinical assistants. Defining and enforcing scope boundaries is a meaningful risk mitigation strategy.

### **Ongoing output auditing.**

Deployment should not be treated as a terminal event. Clinical AI outputs should be logged, reviewed, and analyzed for accuracy over time, with feedback mechanisms that allow identified errors to inform ongoing validation and, where applicable, model refinement.

## **A Shared Responsibility**

Responsible deployment of AI in pharmacy requires engagement from multiple stakeholders.

Healthcare organizations bear responsibility for ensuring that validation appropriate to their clinical context is in place before deployment, and for establishing governance structures that monitor performance over time. The FDA’s evolving guidance on AI in drug development and clinical settings reflects a growing regulatory expectation that organizations demonstrate how AI outputs were validated and what risk controls were applied.

AI developers have a corresponding responsibility to provide transparent, specific documentation of model limitations, evaluation methodology, and known failure modes. General claims of clinical accuracy are not a substitute for rigorous, domain-specific validation evidence.

Pharmacists and clinical staff are essential participants in this process. As the professionals most likely to encounter a problematic output in real time, their domain expertise should inform guardrail design from the outset — and institutional processes should support their ability to flag, escalate, and act on concerns.

## **Conclusion**

AI in pharmacy is neither inherently unsafe nor automatically safe. Its risk profile is determined by how it is designed, validated, deployed, and governed. Where appropriate guardrails are in place — grounded retrieval, uncertainty communication, human oversight, and ongoing auditing — LLMs can contribute meaningfully to pharmacy workflows. Where those guardrails are absent, the gap between model confidence and clinical accuracy can become a significant variable affecting patient safety.

The goal is not to delay beneficial technology. It is to ensure that deployment decisions are made with accurate expectations, appropriate safeguards, and a governance structure capable of identifying and correcting errors as they occur. The healthcare field has consistently demonstrated the ability to integrate new tools responsibly. AI is not an exception to that standard — it is subject to it.

*The views expressed in this article are intended to inform discussion across the healthcare and pharmacy community. This piece does not constitute medical, legal, or regulatory advice.*

*Rohan Desai | Dallas, Texas | BI Analyst | Data Modeller | Healthcare Analytics*

*The contents of external submissions are not necessarily reflective of the opinions or work of* [*Maven Analytics*](http://mavenanalytics.io) *or any of its team members.*

*We believe in fostering lifelong learning and our intent is to provide a platform for the data community to share their work and seek feedback from the Maven Analytics data fam.*

[*Submit your own writing here*](/learning-data/how-to-get-your-work-published-by-learning-data-with-maven-analytics-7df21e466a3e?sk=020dfac485597d602e218968d9ffb395) *if you’d like to become a contributor.*

*Happy learning!*

*\-Team Maven*